NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $2.68 +0.05 (+1.90%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$2.52▼$2.7550-Day Range$2.33▼$5.1152-Week Range$2.05▼$361.60Volume58,246 shsAverage Volume82,909 shsMarket Capitalization$3.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX)Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More BDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDRX Stock News HeadlinesDecember 25, 2023 | uk.finance.yahoo.comBiodexa Pharmaceuticals Plc (BDRX)December 21, 2023 | finance.yahoo.comBiodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment OptionDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionDecember 19, 2023 | msn.comWhy Biodexa Pharmaceuticals (BDRX) Shares Are Getting HammeredDecember 11, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday TradingNovember 30, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Flat in Thursday TradingNovember 29, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Slightly Higher WednesdayNovember 27, 2023 | finance.yahoo.comBiodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 DiabetesDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionOctober 3, 2023 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent GlioblastomaSeptember 21, 2023 | finance.yahoo.comBiodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)August 15, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday's SessionJuly 28, 2023 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials WebsitesJuly 28, 2023 | finance.yahoo.comBiodexa Pharmaceuticals Launches New Corporate and Clinical Trials WebsitesJuly 24, 2023 | marketwatch.comADRs End Mostly Higher; Steakholder Foods, Biodexa Pharmaceuticals Trade ActivelyJuly 24, 2023 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Biodexa Regain Compliance with NASDAQ Minimum Bid Price RequirementJuly 24, 2023 | finance.yahoo.comBiodexa Regain Compliance with NASDAQ Minimum Bid Price RequirementJuly 20, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Modestly ThursdayJuly 10, 2023 | finance.yahoo.comCompletion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)July 6, 2023 | finance.yahoo.comResults of Appeal of Delisting DeterminationJuly 6, 2023 | finance.yahoo.comPublication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)July 6, 2023 | finance.yahoo.comPublication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)June 23, 2023 | finanznachrichten.deBiodexa Pharmaceuticals PLC: ADR Ratio ChangeJune 22, 2023 | finance.yahoo.comADR Ratio ChangeJune 20, 2023 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Appeal of Delisting DeterminationJune 20, 2023 | finance.yahoo.comAppeal of Delisting DeterminationJune 16, 2023 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Receipt of NASDAQ Delisting Determination Plans to AppealSee More Headlines Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BDRX CUSIPN/A CIK1643918 Webwww.midatechpharma.com Phone441235888300FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.07 Current Ratio3.18 Quick RatioN/A Sales & Book Value Annual Sales$870,000.00 Price / Sales3.97 Cash FlowN/A Price / Cash FlowN/A Book Value$57.76 per share Price / Book0.05Miscellaneous Outstanding Shares1,290,000Free Float1,283,000Market Cap$3.46 million OptionableNot Optionable Beta1.95 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Stephen A. Stamp (Age 61)CEO, CFO, Company Sec. & Director Comp: $289.04kDr. Dmitry Zamoryakhin M.D. (Age 43)Chief Scientific Officer Comp: $287.56kDr. Daniel Palmer MBAPh.D., VP of TechnologyMs. Fiona SharpGroup Financial ControllerKey CompetitorsEnsysce BiosciencesNASDAQ:ENSCAptevo TherapeuticsNASDAQ:APVOPetros PharmaceuticalsNASDAQ:PTPIRevelation BiosciencesNASDAQ:REVBAyala PharmaceuticalsNASDAQ:ADXSView All Competitors BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed in 2023? Biodexa Pharmaceuticals' stock was trading at $33.7360 at the beginning of 2023. Since then, BDRX stock has decreased by 92.1% and is now trading at $2.68. View the best growth stocks for 2023 here. When did Biodexa Pharmaceuticals' stock split? Shares of Biodexa Pharmaceuticals reverse split on the morning of Wednesday, July 5th 2023. The 1-80 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BDRX) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.